Inhibikase Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inhibikase Therapeutics (IKT).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$5Upside to Avg. PT+191.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Chardan Capital	Andreas Argyrides	Initiate	Neutral	$2
Jun 10, 2026	Oppenheimer	—	Initiate	Outperform	$5
Mar 4, 2026	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$4
Jan 21, 2026	B of A Securities	Jason Zemansky	Initiate	Buy	$6
Dec 26, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$8
Dec 17, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$3
Dec 11, 2025	Cantor Fitzgerald	Olivia Brayer	Initiate	Overweight	$4
Mar 28, 2025	HC Wainwright & Co.	Edward White	Maintained	Neutral	—
Feb 12, 2025	HC Wainwright & Co.	Edward White	Downgrade	Buy→Neutral	—
Nov 8, 2024	Jefferies	Dennis Ding	Initiate	Buy	$8
Oct 14, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$15→$5
Aug 16, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$23→$15
May 21, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$27→$23
Mar 7, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$27
Mar 5, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.

Benzinga Newsdesk

Inhibikase Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Inhibikase Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

People Also Watch

People Also Watch

Inhibikase Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Inhibikase Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROChardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PROOppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PROLadenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PROB of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PROHC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PROCantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

People Also Watch

People Also Watch

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4